A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy ; volume:7 ; number:1 ; day:16 ; month:5 ; year:2019 ; pages:1-5 ; date:12.2019
Journal for ImmunoTherapy of Cancer ; 7, Heft 1 (16.5.2019), 1-5, 12.2019
- Creator
-
Ornstein, Moshe C.
Wood, Laura S.
Hobbs, Brian P.
Allman, Kimberly D.
Martin, Allison
Bevan, Michael
Gilligan, Timothy D.
Garcia, Jorge A.
Rini, Brian I.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40425-019-0615-z
- URN
-
urn:nbn:de:101:1-2019100200125034114822
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:39 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ornstein, Moshe C.
- Wood, Laura S.
- Hobbs, Brian P.
- Allman, Kimberly D.
- Martin, Allison
- Bevan, Michael
- Gilligan, Timothy D.
- Garcia, Jorge A.
- Rini, Brian I.
- SpringerLink (Online service)
Other Objects (12)
Anti-angiogenic therapies in brain metastases
Anti-angiogenic alternatives to VEGF blockade
Future options of anti-angiogenic cancer therapy
Correction: Beyond starving cancer: anti-angiogenic therapy
Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy
Characterization of anti-angiogenic therapy response in glioblastoma
Anti-angiogenic therapies for advanced esophago-gastric cancer
Perforated Gastric Ulcer Associated with Anti-Angiogenic Therapy
Comparison of anti-angiogenic properties of pristine carbon nanoparticles
Proteomic analysis predicts anti-angiogenic resistance in recurred glioblastoma
Anti-angiogenic effect of high doses of ascorbic acid
AntAngioCOOL: computational detection of anti-angiogenic peptides
Anti-angiogenic therapies in brain metastases
Anti-angiogenic alternatives to VEGF blockade
Future options of anti-angiogenic cancer therapy
Correction: Beyond starving cancer: anti-angiogenic therapy
Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy
Characterization of anti-angiogenic therapy response in glioblastoma
Anti-angiogenic therapies for advanced esophago-gastric cancer
Perforated Gastric Ulcer Associated with Anti-Angiogenic Therapy
Comparison of anti-angiogenic properties of pristine carbon nanoparticles
Proteomic analysis predicts anti-angiogenic resistance in recurred glioblastoma
Anti-angiogenic effect of high doses of ascorbic acid
AntAngioCOOL: computational detection of anti-angiogenic peptides
Anti-angiogenic therapies in brain metastases
Anti-angiogenic alternatives to VEGF blockade
Future options of anti-angiogenic cancer therapy
Correction: Beyond starving cancer: anti-angiogenic therapy
Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy
Characterization of anti-angiogenic therapy response in glioblastoma
Anti-angiogenic therapies for advanced esophago-gastric cancer
Perforated Gastric Ulcer Associated with Anti-Angiogenic Therapy
Comparison of anti-angiogenic properties of pristine carbon nanoparticles
Proteomic analysis predicts anti-angiogenic resistance in recurred glioblastoma
Anti-angiogenic effect of high doses of ascorbic acid